Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 6 | 2024 | 132 | 3.620 |
Why?
|
| Head and Neck Neoplasms | 10 | 2024 | 1061 | 3.070 |
Why?
|
| Papillomavirus Infections | 6 | 2024 | 264 | 2.750 |
Why?
|
| Carcinoma | 2 | 2022 | 438 | 1.210 |
Why?
|
| Papillomaviridae | 3 | 2022 | 156 | 1.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 2506 | 0.990 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 1185 | 0.910 |
Why?
|
| Quinolones | 1 | 2024 | 56 | 0.880 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.820 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2024 | 341 | 0.800 |
Why?
|
| Patient Care | 1 | 2022 | 102 | 0.760 |
Why?
|
| Fluorouracil | 2 | 2022 | 549 | 0.760 |
Why?
|
| Drug Monitoring | 1 | 2022 | 118 | 0.740 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 376 | 0.740 |
Why?
|
| DNA, Viral | 1 | 2022 | 263 | 0.740 |
Why?
|
| Cancer Survivors | 1 | 2022 | 95 | 0.730 |
Why?
|
| Immunotherapy | 2 | 2024 | 698 | 0.720 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.710 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2020 | 47 | 0.710 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 425 | 0.620 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2018 | 9 | 0.610 |
Why?
|
| Carboplatin | 3 | 2024 | 312 | 0.580 |
Why?
|
| Paclitaxel | 3 | 2024 | 474 | 0.550 |
Why?
|
| Thalassemia | 1 | 2016 | 16 | 0.530 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 288 | 0.520 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 293 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1352 | 0.480 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 144 | 0.450 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2025 | 43 | 0.430 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2025 | 80 | 0.410 |
Why?
|
| Humans | 22 | 2025 | 89970 | 0.410 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 2331 | 0.370 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 152 | 0.370 |
Why?
|
| Mouth Neoplasms | 2 | 2022 | 199 | 0.340 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 716 | 0.330 |
Why?
|
| Chemoradiotherapy | 2 | 2022 | 306 | 0.330 |
Why?
|
| Feasibility Studies | 2 | 2022 | 785 | 0.300 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 1545 | 0.300 |
Why?
|
| Middle Aged | 6 | 2024 | 26148 | 0.260 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 165 | 0.260 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2025 | 21 | 0.240 |
Why?
|
| Female | 8 | 2025 | 46595 | 0.230 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 2587 | 0.220 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 67 | 0.210 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 476 | 0.210 |
Why?
|
| Cisplatin | 2 | 2022 | 598 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 268 | 0.210 |
Why?
|
| Cancer Vaccines | 1 | 2024 | 159 | 0.210 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 134 | 0.210 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2023 | 113 | 0.200 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.200 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 278 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 280 | 0.200 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.200 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 36 | 0.190 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 263 | 0.190 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 70 | 0.190 |
Why?
|
| Male | 6 | 2024 | 42682 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 46 | 0.190 |
Why?
|
| Proteomics | 1 | 2023 | 232 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 405 | 0.190 |
Why?
|
| Adult | 4 | 2024 | 26822 | 0.180 |
Why?
|
| Nomograms | 1 | 2020 | 32 | 0.180 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 1066 | 0.170 |
Why?
|
| Esophagogastric Junction | 1 | 2019 | 34 | 0.160 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2019 | 28 | 0.160 |
Why?
|
| Aged | 3 | 2024 | 19254 | 0.160 |
Why?
|
| Neutropenia | 1 | 2019 | 214 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 416 | 0.150 |
Why?
|
| Diarrhea | 1 | 2019 | 178 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 422 | 0.140 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 865 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2018 | 66 | 0.140 |
Why?
|
| Young Adult | 2 | 2022 | 6410 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1704 | 0.140 |
Why?
|
| Bone and Bones | 1 | 2018 | 271 | 0.130 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 1169 | 0.130 |
Why?
|
| Infant | 1 | 2023 | 3191 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 1098 | 0.120 |
Why?
|
| Sex Factors | 1 | 2018 | 1075 | 0.120 |
Why?
|
| Prognosis | 1 | 2022 | 3798 | 0.110 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 2000 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 1801 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2022 | 4331 | 0.110 |
Why?
|
| Liver | 1 | 2018 | 1211 | 0.110 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3680 | 0.100 |
Why?
|
| Survival Rate | 1 | 2016 | 1899 | 0.100 |
Why?
|
| Lung | 1 | 2018 | 1292 | 0.090 |
Why?
|
| Time Factors | 1 | 2019 | 5359 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2022 | 8273 | 0.080 |
Why?
|
| Adolescent | 1 | 2022 | 9342 | 0.080 |
Why?
|
| Neoplasms | 1 | 2023 | 3065 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2023 | 3404 | 0.070 |
Why?
|
| Risk Factors | 1 | 2016 | 5559 | 0.060 |
Why?
|
| Histone Demethylases | 1 | 2023 | 32 | 0.060 |
Why?
|
| Animals | 4 | 2025 | 27528 | 0.050 |
Why?
|
| Longevity | 1 | 2023 | 58 | 0.050 |
Why?
|
| Genes, ras | 1 | 2023 | 97 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2025 | 485 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2022 | 293 | 0.050 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 95 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2022 | 126 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 231 | 0.050 |
Why?
|
| Models, Animal | 1 | 2022 | 277 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 332 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 495 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 569 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 644 | 0.040 |
Why?
|
| Aging | 1 | 2023 | 727 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2025 | 1669 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 661 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1665 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1682 | 0.030 |
Why?
|
| Mice | 1 | 2025 | 11851 | 0.020 |
Why?
|